X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-14 | BHC | Bausch Health Companies Inc. | Paulson John | Dir | P - Purchase | $9.00 | +34,721,118 | 70,755,869 | +96% | +$312,490,062 | ||||||
| D | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | Moore John R | GC | S - Sale+OE | $13.39 | -2,098 | 10,214 | -17% | -$28,097 | |||||
| D | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | Derakhshan Behrad | Chief Business Officer | S - Sale+OE | $13.39 | -2,491 | 23,645 | -10% | -$33,360 | |||||
| D | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | Carruthers R Michael | CFO | S - Sale+OE | $13.39 | -1,428 | 86,162 | -2% | -$19,124 | |||||
| D | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | Russell Alan J | Chief Scientific Officer | S - Sale+OE | $13.39 | -1,907 | 23,400 | -8% | -$25,539 | |||||
| D | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | Koch Kevin | Pres, CEO | S - Sale+OE | $13.39 | -7,972 | 369,399 | -2% | -$106,764 | |||||
| D | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale+OE | $13.39 | -2,862 | 25,361 | -10% | -$38,329 | |||||
| DM | 2025-08-12 | RYTM | Rhythm Pharmaceuticals, Inc. | Smith Hunter C | CFO | S - Sale+OE | $96.29 | -28,088 | 116,915 | -19% | -$2,704,624 | |||||
| D | 2025-08-12 | RYTM | Rhythm Pharmaceuticals, Inc. | German Christopher Paul | Corporate Controller, CAO | S - Sale+OE | $95.00 | -1,500 | 922 | -62% | -$142,500 | |||||
| D | 2025-08-13 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $12.93 | -11,365 | 92,891 | -11% | -$146,987 | |||||
2025-08-12 | ANIP | Ani Pharmaceuticals Inc | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | S - Sale | $85.71 | -4,975 | 40,794 | -11% | -$426,407 | ||||||
2025-08-12 | ANIP | Ani Pharmaceuticals Inc | Lalwani Nikhil | Pres, CEO | S - Sale | $85.93 | -56,960 | 411,219 | -12% | -$4,894,573 | ||||||
2025-08-12 | ANIP | Ani Pharmaceuticals Inc | Gutwerg Ori | SVP, GENERICS | S - Sale | $86.53 | -5,873 | 84,024 | -7% | -$508,191 | ||||||
2025-08-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $88.87 | -400 | 76,474 | -1% | -$35,548 | ||||||
| D | 2025-08-12 | ANIP | Ani Pharmaceuticals Inc | Carey Stephen P. | SVP, CFO | S - Sale+OE | $86.07 | -50,000 | 180,863 | -22% | -$4,303,500 | |||||
2025-08-12 | ANIP | Ani Pharmaceuticals Inc | Haughey Thomas | Dir | S - Sale | $85.93 | -19,341 | 36,521 | -35% | -$1,661,972 | ||||||
| DM | 2025-08-12 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $34.84 | -96,387 | 536,962 | -15% | -$3,357,842 | |||||
| D | 2025-08-12 | ABBV | Abbvie Inc. | Saleki-Gerhardt Azita | EVP, CHIEF OPERATIONS OFFICER | S - Sale+OE | $198.42 | -42,370 | 183,812 | -19% | -$8,407,055 | |||||
| DM | 2025-08-12 | KNSA | Kiniksa Pharmaceuticals International, Plc | Malley Thomas | Dir | S - Sale+OE | $32.96 | -177,769 | 84,513 | -68% | -$5,859,815 | |||||
| D | 2025-08-12 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $5.25 | -5,500 | 0 | -100% | -$28,875 | |||||
2025-08-12 | INSM | Insmed Inc | Sharoky Melvin Md | Dir | S - Sale | $121.58 | -10,000 | 334,378 | -3% | -$1,215,800 | ||||||
| M | 2025-08-12 | AMLX | Amylyx Pharmaceuticals, Inc. | Mazzariello Gina | GC | S - Sale | $8.20 | -30,000 | 156,969 | -16% | -$246,149 | |||||
2025-08-13 | DSGN | Design Therapeutics, Inc. | William Arsani | Dir | S - Sale | $5.25 | -562,627 | 3,655,000 | -13% | -$2,953,792 | ||||||
2025-08-13 | LLY | Eli Lilly & Co | Alvarez Ralph | Dir | P - Purchase | $660.25 | +758 | 55,753 | +1% | +$500,473 | ||||||
| M | 2025-08-12 | KURA | Kura Oncology, Inc. | Wilson Troy Edward | Pres, CEO | P - Purchase | $6.06 | +50,000 | 630,162 | +9% | +$303,201 | |||||
| M | 2025-08-11 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Pres, CEO | S - Sale | $10.43 | -797 | 34,828 | -2% | -$8,313 | |||||
| M | 2025-08-11 | LYEL | Lyell Immunopharma, Inc. | Hill Stephen J. | COO | S - Sale | $10.43 | -185 | 8,849 | -2% | -$1,930 | |||||
| M | 2025-08-11 | LYEL | Lyell Immunopharma, Inc. | Lee Gary K. | Chief Scientific Officer | S - Sale | $10.43 | -267 | 8,957 | -3% | -$2,785 | |||||
| M | 2025-08-11 | LYEL | Lyell Immunopharma, Inc. | Newton Charles W. | CFO | S - Sale | $10.43 | -267 | 18,759 | -1% | -$2,785 | |||||
| D | 2025-08-13 | WVE | Wave Life Sciences Ltd. | Henry Christian O | Dir | S - Sale+OE | $8.81 | -9,670 | 29,645 | -25% | -$85,193 | |||||
| M | 2025-08-11 | BHC | Bausch Health Companies Inc. | Paulson John | Dir | P - Purchase | $6.56 | +3,243,049 | 36,034,751 | +10% | +$21,267,731 | |||||
| D | 2025-08-12 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | COO | S - Sale+OE | $47.79 | -12,500 | 257,484 | -5% | -$597,326 | |||||
2025-08-11 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Pres, CEO | S - Sale | $48.59 | -30,000 | 490,757 | -6% | -$1,457,596 | ||||||
| D | 2025-08-11 | RYTM | Rhythm Pharmaceuticals, Inc. | Shulman Joseph | Chief Technical Officer | S - Sale+OE | $90.08 | -3,984 | 8,509 | -32% | -$358,891 | |||||
| D | 2025-08-13 | MDGL | Madrigal Pharmaceuticals, Inc. | Friedman Paul A | Dir | S - Sale+OE | $370.24 | -129,172 | 842,704 | -13% | -$47,825,149 | |||||
2025-08-12 | VTRS | Viatris Inc | Smith Scott Andrew | CEO | P - Purchase | $9.99 | +22,000 | 314,807 | +8% | +$219,740 | ||||||
2025-08-11 | ALDX | Aldeyra Therapeutics, Inc. | Machatha Stephen | Chief Development Officer | S - Sale | $5.15 | -22,073 | 221,799 | -9% | -$113,713 | ||||||
| D | 2025-08-11 | LGVN | Longeveron Inc. | Locklear Lisa | CFO | P - Purchase | $0.00 | +11,766 | 250,964 | +5% | +$0 | |||||
| D | 2025-08-11 | LGVN | Longeveron Inc. | Baluch Khoso | Dir | P - Purchase | $0.00 | +11,766 | 52,516 | +29% | +$0 | |||||
| DM | 2025-08-11 | MDGL | Madrigal Pharmaceuticals, Inc. | Friedman Paul A | Dir | S - Sale+OE | $355.31 | -46,808 | 842,704 | -5% | -$16,631,386 | |||||
| DM | 2025-08-11 | MDGL | Madrigal Pharmaceuticals, Inc. | Taub Rebecca | Dir | S - Sale+OE | $355.32 | -46,463 | 1,116,584 | -4% | -$16,509,032 | |||||
2025-08-11 | NAMS | Newamsterdam Pharma Co N.V. | Topper James N | Dir | P - Purchase | $23.98 | +471 | 6,827,604 | 0% | +$11,294 | ||||||
2025-08-12 | XERS | Xeris Biopharma Holdings, Inc. | Halkuff Dawn | Dir | S - Sale | $7.28 | -42,500 | 120,410 | -26% | -$309,226 | ||||||
2025-08-12 | AMRX | Amneal Pharmaceuticals, Inc. | Shah Nikita | EVP | S - Sale | $9.04 | -50,000 | 338,929 | -13% | -$452,000 | ||||||
2025-08-12 | AMRX | Amneal Pharmaceuticals, Inc. | Daly Jason B. | EVP, GC | S - Sale | $9.05 | -22,000 | 10,606 | -67% | -$199,100 | ||||||
2025-08-12 | AMRX | Amneal Pharmaceuticals, Inc. | Boyer Andrew S | EVP | S - Sale | $9.05 | -33,436 | 256,670 | -12% | -$302,596 | ||||||
2025-08-12 | EBS | Emergent Biosolutions Inc. | Degolyer Donald W | Dir | S - Sale | $8.65 | -7,844 | 137,659 | -5% | -$67,831 | ||||||
2025-08-13 | LLY | Eli Lilly & Co | Van Naarden Jacob | EVP, Pres, Lilly Oncology | P - Purchase | $647.36 | +1,000 | 29,206 | +4% | +$647,360 | ||||||
| D | 2025-08-07 | BIVI | Biovie Inc. | Do Cuong V | Pres, CEO | P - Purchase | $0.00 | +5,000 | 9,992 | +100% | +$0 | |||||
2025-08-11 | IRWD | Ironwood Pharmaceuticals Inc | Gaskins Tammi L | Chief Commercial Officer | S - Sale | $0.84 | -1,316 | 241,280 | -1% | -$1,105 | ||||||
2025-08-11 | IRWD | Ironwood Pharmaceuticals Inc | John Minardo | GC | S - Sale | $0.84 | -7,754 | 400,378 | -2% | -$6,513 | ||||||
2025-08-11 | IRWD | Ironwood Pharmaceuticals Inc | Martini Gregory S. | CFO | S - Sale | $0.84 | -1,265 | 182,545 | -1% | -$1,063 | ||||||
2025-08-11 | IRWD | Ironwood Pharmaceuticals Inc | Silver Ronald | Principal Accounting Officer | S - Sale | $0.84 | -2,846 | 276,809 | -1% | -$2,391 | ||||||
| M | 2025-08-11 | ZOMDF | Zomedica Corp. | Klass Russell Kevin | SVP, Sales | P - Purchase | $0.04 | +1,056,064 | 5,256,094 | +25% | +$42,243 | |||||
2025-08-11 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | S - Sale | $17.69 | -10,000 | 148,229 | -6% | -$176,900 | ||||||
| D | 2025-08-12 | AKRO | Akero Therapeutics, Inc. | Henderson Jane | Dir | S - Sale+OE | $47.46 | -3,000 | 9,398 | -24% | -$142,371 | |||||
| D | 2025-08-11 | MIRM | Mirum Pharmaceuticals, Inc. | Bjerkholt Eric | CFO | S - Sale+OE | $0.00 | -8,000 | 31,190 | -20% | -$0 | |||||
| D | 2025-08-11 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale+OE | $62.00 | -40,000 | 347,211 | -10% | -$2,480,000 | |||||
| D | 2025-08-11 | CORT | Corcept Therapeutics Inc | Swisher Daniel N Jr | Dir | S - Sale+OE | $72.30 | -2,200 | 0 | -100% | -$159,060 | |||||
| D | 2025-08-08 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $71.77 | -35,007 | 5,487 | -86% | -$2,512,452 | |||||
| M | 2025-08-08 | BBIO | Bridgebio Pharma, Inc. | Homcy Charles J | Dir | S - Sale | $46.37 | -300,000 | 916,674 | -25% | -$13,912,443 | |||||
| D | 2025-08-08 | HRTX | Heron Therapeutics, Inc. /De/ | Rubric Capital Management LP | 10% | P - Purchase | $1.50 | +2,387,225 | 29,100,728 | +9% | +$3,580,838 | |||||
2025-08-08 | COLL | Collegium Pharmaceutical, Inc | Freund John Gordon | Dir | S - Sale | $34.36 | -11,659 | 102,412 | -10% | -$400,641 | ||||||
2025-08-08 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale | $14.03 | -3,847 | 108,999 | -3% | -$53,988 | ||||||
| D | 2025-08-08 | HRTX | Heron Therapeutics, Inc. /De/ | Morgan Adam | Dir | P - Purchase | $1.50 | +1,766,546 | 8,823,067 | +25% | +$2,649,819 | |||||
2025-08-08 | ZLAB | Zai Lab Ltd | Amado Rafael | See Remarks | S - Sale | $35.00 | -3,000 | 42,178 | -7% | -$105,000 | ||||||
2025-08-08 | ZLAB | Zai Lab Ltd | Chen Yajing | CFO | S - Sale | $34.01 | -4,096 | 16,908 | -20% | -$139,305 | ||||||
| DM | 2025-08-08 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $34.69 | -100,000 | 536,962 | -16% | -$3,468,970 | |||||
| D | 2025-08-08 | AGIO | Agios Pharmaceuticals, Inc. | Goff Brian | CEO | S - Sale+OE | $36.67 | -11,085 | 123,528 | -8% | -$406,487 | |||||
2025-08-12 | LLY | Eli Lilly & Co | Ricks David A | Pres, Chair,, CEO | P - Purchase | $644.77 | +1,632 | 676,970 | 0% | +$1,052,263 | ||||||
2025-08-12 | LLY | Eli Lilly & Co | Skovronsky Daniel | EVP, CSO, Pres LRL, LLY Imm | P - Purchase | $634.41 | +1,000 | 213,276 | 0% | +$634,405 | ||||||
2025-08-12 | LLY | Eli Lilly & Co | Sulzberger Gabrielle | Dir | P - Purchase | $641.18 | +117 | 2,703 | +5% | +$75,018 | ||||||
2025-08-12 | LLY | Eli Lilly & Co | Fyrwald J Erik | Dir | P - Purchase | $642.33 | +1,565 | 74,578 | +2% | +$1,005,242 | ||||||
2025-08-11 | LLY | Eli Lilly & Co | Yuffa Ilya | EVP, Pres, LLY USA, Global Cap | S - Sale | $627.01 | -1,250 | 26,260 | -5% | -$783,763 | ||||||
| D | 2025-08-08 | ANAB | Anaptysbio, Inc | Renton Hollings | Dir | S - Sale+OE | $19.62 | -10,231 | 4,965 | -67% | -$200,714 | |||||
2025-08-11 | ZOMDF | Zomedica Corp. | Klass Russell Kevin | SVP of Sales | P - Purchase | $0.04 | +500,000 | 4,200,030 | +14% | +$19,500 | ||||||
2025-08-08 | ZOMDF | Zomedica Corp. | Klass Russell Kevin | SVP of Sales | P - Purchase | $0.04 | +500,000 | 3,700,030 | +16% | +$20,000 | ||||||
2025-08-08 | ITRM | Iterum Therapeutics Plc | Dunne Michael W. | Dir | P - Purchase | $0.72 | +15,000 | 235,001 | +7% | +$10,854 | ||||||
2025-08-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $18.24 | -6,667 | 289,975 | -2% | -$121,616 | ||||||
2025-08-07 | BBIO | Bridgebio Pharma, Inc. | Apuli Maricel | Chief Accounting Officer | S - Sale | $45.44 | -1,000 | 141,859 | -1% | -$45,440 | ||||||
| M | 2025-08-07 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $45.84 | -80,000 | 5,851,537 | -1% | -$3,666,949 | |||||
2025-08-08 | ABT | Abbott Laboratories | Boudreau Philip P | EVP, CFO | S - Sale | $134.55 | -5,550 | 51,364 | -10% | -$746,758 | ||||||
| M | 2025-06-17 | BYSI | Beyondspring Inc. | Decheng Capital China Life Sciences Usd Fund Iii, L.P. | 10% | S - Sale | $3.05 | -394,436 | 4,488,215 | -8% | -$1,204,042 | |||||
| D | 2025-08-11 | RPRX | Royalty Pharma Plc | Norden Gregory | Dir | S - Sale+OE | $36.23 | -33,500 | 194,848 | -15% | -$1,213,749 | |||||
2025-08-07 | PCRX | Pacira Biosciences, Inc. | Bigal Marcelo | Dir | S - Sale | $23.67 | -4,912 | 11,393 | -30% | -$116,267 | ||||||
| M | 2025-07-01 | CPIX | Cumberland Pharmaceuticals Inc | Young Caroline | Dir | P - Purchase | $3.44 | +168 | 32,821 | +1% | +$578 | |||||
| M | 2025-07-01 | CPIX | Cumberland Pharmaceuticals Inc | Jones James | Dir | P - Purchase | $3.43 | +340 | 43,676 | +1% | +$1,166 | |||||
| M | 2025-07-01 | CPIX | Cumberland Pharmaceuticals Inc | Kazimi A J | COB, CEO, 10% | P - Purchase | $3.43 | +340 | 5,699,768 | 0% | +$1,166 | |||||
| M | 2025-07-01 | CPIX | Cumberland Pharmaceuticals Inc | Krogulski Kenneth | Dir | P - Purchase | $3.43 | +1,712 | 288,345 | +1% | +$5,872 | |||||
2025-08-06 | IONS | Ionis Pharmaceuticals Inc | Parshall B Lynne | Dir | S - Sale | $41.93 | -5,000 | 86,344 | -5% | -$209,646 | ||||||
| D | 2025-08-06 | RNA | Avidity Biosciences, Inc. | Mosbrooker Eric | Chief Commercial Officer | S - Sale+OE | $44.06 | -130,807 | 55,000 | -70% | -$5,763,697 | |||||
| D | 2025-08-06 | RNA | Avidity Biosciences, Inc. | Wilson Troy Edward | Dir | S - Sale+OE | $45.00 | -95,054 | 712,390 | -12% | -$4,277,430 | |||||
| D | 2025-08-06 | RNA | Avidity Biosciences, Inc. | Levin Arthur A | Dir | S - Sale+OE | $47.62 | -107,500 | 173,522 | -38% | -$5,118,881 | |||||
| D | 2025-08-06 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Chief Medical Officer | S - Sale+OE | $42.74 | -81,434 | 38,867 | -68% | -$3,480,269 | |||||
2025-08-08 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.32 | +675,000 | 248,372,576 | 0% | +$891,000 | ||||||
| D | 2025-08-07 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | SVP, GLOBAL CONTROLLER | S - Sale+OE | $58.00 | -10,000 | 2,426 | -80% | -$580,000 | |||||
| D | 2025-08-07 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale+OE | $55.25 | -40,000 | 347,211 | -10% | -$2,210,040 | |||||
| D | 2025-08-06 | SUPN | Supernus Pharmaceuticals, Inc. | Khattar Jack A. | Pres, CEO | S - Sale+OE | $42.02 | -140,000 | 2,075,533 | -6% | -$5,883,360 | |||||
| D | 2025-08-06 | KNSA | Kiniksa Pharmaceuticals International, Plc | Paolini John F. | CHIEF MEDICAL OFFICER | S - Sale+OE | $32.55 | -29,325 | 57,403 | -34% | -$954,529 | |||||
| D | 2025-08-07 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $300.00 | -11,000 | 36,781 | -23% | -$3,299,981 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |